

DAFTAR PUSTAKA

- Aritomi, S. (2012) 'Cilnidipine, An L-/N-Type Calcium Channel Blocker, Changes the Circulating Angiotensin-(1-7)/Angiotensin II Ratio', *Journal of Hypertension- Open Access*, 01(01), pp. 1–6. doi: 10.4172/2167-1095.1000102.
- Bai, S. *et al.* (2013) 'Effects of felodipine combined with puerarin on ACE2-Ang (1-7)-Mas axis in renovascular hypertensive rat', *Regulatory Peptides*, 184, pp. 54–61. doi: 10.1016/j.regpep.2013.03.005.
- Bosso, M. *et al.* (2020) 'The Two Faces of ACE2: The Role of ACE2 Receptor and Its Polymorphisms in Hypertension and COVID-19', *Molecular Therapy - Methods and Clinical Development*, 18(September), pp. 321–327. doi: 10.1016/j.omtm.2020.06.017.
- Bulsara, Kishen G. ; Cassagnol, M. (2023) *Amlodipine*. Statpearls Publishing. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK519508/#:~:text=Peak plasma concentrations are achieved,approximately 40%25 to 60%25>.
- Burrell, L. M. *et al.* (2012) 'Chronic kidney disease: Cardiac and renal angiotensin-converting enzyme (ACE) 2 expression in rats after subtotal nephrectomy and the effect of ACE inhibition', *Experimental Physiology*, 97(4), pp. 477–485. doi: 10.1113/expphysiol.2011.063156.
- Babadaei, M. M. N. *et al.* (2020) 'The expression level of angiotensin-converting enzyme 2 determines the severity of COVID-19: lung and heart tissue as targets', *Journal of Biomolecular Structure and Dynamics*, 0(0), pp. 1–7. doi: 10.1080/07391102.2020.1767211.
- Bakhle, Y. S. (2020) 'How ACE inhibitors transformed the renin–angiotensin system', *British Journal of Pharmacology*, 177(12), pp. 2657–2665. doi: 10.1111/bph.15045.
- Beyerstedt, S., Casaro, E. B. and Rangel, É. B. (2021) 'COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection', 2.
- Chiong, J. R. *et al.* (2008) 'Secondary hypertension: Current diagnosis and treatment', 124, pp. 6–21. doi: 10.1016/j.ijcard.2007.01.119.
- Chouchana, L. *et al.* (2021) 'Correction to: Association of Antihypertensive Agents with the Risk of In-Hospital Death in Patients with Covid-19 (Cardiovascular Drugs and Therapy, (2021), 10.1007/s10557-021-07155-5)', *Cardiovascular Drugs and Therapy*, pp. 6–11. doi: 10.1007/s10557-021-07164-4.
- D'elia, J. A. and Weinrauch, L. A. (2018) 'Calcium ion channels: Roles in infection and sepsis mechanisms of calcium channel blocker benefits in immunocompromised patients at risk for infection', *International Journal of Molecular Sciences*, 19(9), pp. 1–17. doi: 10.3390/ijms19092465.
- Dambha-Miller, H. *et al.* (2020) 'Currently prescribed drugs in the UK that could upregulate or downregulate ACE2 in COVID-19 disease: A systematic

review', *BMJ Open*, 10(9), pp. 1–10. doi: 10.1136/bmjopen-2020-040644.

- Devaux, C. A., Rolain, J.-M. and Raoult, D. (2020) 'ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome', *Journal of Microbiology, Immunology and Infection*, 53(3), pp. 425–435. doi: <https://doi.org/10.1016/j.jmii.2020.04.015>.
- Diaz, J. H. (2021) 'Hypothesis: Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19', *Journal of Travel Medicine*, 27(3), pp. 1–7. doi: 10.1093/JTM/TAAA041.
- Fan, L. *et al.* (2014) 'Hypoxia induces dysregulation of local renin-angiotensin system in mouse Lewis lung carcinoma cells', *Genetics and Molecular Research*, 13(4), pp. 10562–10573. doi: 10.4238/2014.December.12.19.
- Fang, Q. *et al.* (2019) 'Amlodipine induces vasodilation via Akt2/Sp1-activated miR-21 in smooth muscle cells', *British Journal of Pharmacology*, 176(13), pp. 2306–2320. doi: 10.1111/bph.14679.
- Flores-Monroy, J. *et al.* (2014) 'Comparative effects of a novel angiotensin-converting enzyme inhibitor versus captopril on plasma angiotensins after myocardial infarction', *Pharmacology*, 94, pp. 21–28. doi: 10.1159/000365093.
- Fountain JH, L. S. (2021) *Physiology, Renin Angiotensin System*. Statpearls Publishing. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK470410/> (Accessed: 11 December 2021).
- Gao, C. *et al.* (2020) 'Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study', *European Heart Journal*, 41(22), pp. 2058–2066. doi: 10.1093/eurheartj/ehaa433.
- Gao, W. C. *et al.* (2021) 'Captopril alleviates lung inflammation in SARS-CoV-2-infected hypertensive mice', *Zoological Research*, 42(5), pp. 633–636. doi: 10.24272/J.ISSN.2095-8137.2021.206.
- García-Escobar, A. *et al.* (2022) 'Calcium Signaling Pathway Is Involved in the Shedding of ACE2 Catalytic Ectodomain: New Insights for Clinical and Therapeutic Applications of ACE2 for COVID-19', *Biomolecules*, 12(1), pp. 1–17. doi: 10.3390/biom12010076.
- Gembardt, F. *et al.* (2005) 'Organ-specific distribution of ACE2 mRNA and correlating peptidase activity in rodents', 26, pp. 1270–1277. doi: 10.1016/j.peptides.2005.01.009.
- Green, L. (2003) 'JNC 7 express: New thinking in hypertension treatment', *American Family Physician*, 68(2).
- Hall, J. E. (2017) *Guyton and Hall: Textbook of Medical Physiology*. 13th edn, Elsevier. 13th edn. United States of America: Elsevier. doi:

10.4103/sni.sni_327_17

- Hall, J. E. (2017) *Guyton and Hall: Textbook of Medical Physiology*. 13th edn, Elsevier. 13th edn. United States of America: Elsevier. doi: 10.4103/sni.sni_327_17.
- Hamming, ME Cooper, BL Haagmans, NM Hooper, R Korstanje, ADME Osterhaus, W Timens, AJ Turner, G. N. and H. van G. (2007) 'The emerging role of ACE2 in physiology and disease', pp. 1–11. doi: 10.1002/path.
- Haralambos Gavras, I. G. (1988) 'Angiotensin Converting Enzyme Inhibitors Properties and Side Effects', *American Heart Association*, 58 Suppl 2, pp. 135–139. doi: https://doi.org/10.1161/01.HYP.11.3_Pt_2.II37.
- Heran, B. S. *et al.* (2008) 'Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension', *Cochrane Database of Systematic Reviews*, (4). doi: 10.1002/14651858.CD003823.pub2.
- Herman LL, Padala SA, Ahmed I, *et al.* (2021) *Angiotensin Converting Enzyme Inhibitors (ACEI)*, StatPearls Publishing LLC. Available at: https://www.ncbi.nlm.nih.gov/books/NBK431051/#_NBK431051_pubdet_.
- Iizuka, K. *et al.* (2009) 'Angiotensin II reduces membranous angiotensin-converting enzyme 2 in pressurized human aortic endothelial cells', *JRAAS - Journal of the Renin-Angiotensin-Aldosterone System*, 10(4), pp. 210–215. doi: 10.1177/1470320309343710.
- Jacobs, M. *et al.* (2020) 'Increased expression of ACE2, the SARS-CoV-2 entry receptor, in alveolar and bronchial epithelium of smokers and COPD subjects', *European Respiratory Journal*, 56(2). doi: 10.1183/13993003.02378-2020.
- James, P. A. *et al.* (2014) '2014 Evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8)', *JAMA - Journal of the American Medical Association*, 311(5), pp. 507–520. doi: 10.1001/jama.2013.284427.
- Jarari, N. *et al.* (2015) 'A review on prescribing patterns of antihypertensive drugs', *Clinical Hypertension*, 22(1), pp. 1–8. doi: 10.1186/s40885-016-0042-0.
- Jayaseelan, V. P. and Paramasivam, A. (2020) 'Repurposing calcium channel blockers as antiviral drugs', *Journal of Cell Communication and Signaling*, 14(4), pp. 467–468. doi: 10.1007/s12079-020-00579-y.
- Jia, H., Neptune, E. and Cui, H. (2021) 'Targeting ACE2 for COVID-19 Therapy: Opportunities and challenges', *American Journal of Respiratory Cell and Molecular Biology*, 64(4), pp. 416–425. doi: 10.1165/rcmb.2020-0322PS.
- Kaplan, N. (2010) 'Primary hypertension: pathogenesis', in *Kaplan's clinical hypertension*. 10th edn. Philadelphia: Lippincot Williams & Wilkins, pp. 44–108.

- Karmouty-quintana, H., Thandavarayan, R. A. and Keller, S. P. (2020) 'Emerging Mechanisms of Pulmonary Vasoconstriction in SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS) and Potential Therapeutic Targets', *International Journal of Molecular Sciences*, 2(Oktober 2020), pp. 1–21. doi: <https://doi.org/10.3390/ijms21218081>.
- Kemenkes RI (2019) 'Hipertensi Si Pembunuh Senyap', *Kemntrian Kesehatan RI*, pp. 1–5. Available at: <https://pusdatin.kemkes.go.id/resources/download/pusdatin/infodatin/infodatin-hipertensi-si-pembunuh-senyap.pdf>.
- Kementerian Kesehatan, R. (2019) 'KEPUTUSAN MENTERI KESEHATAN REPUBLIK INDONESIA NOMOR HK.01.07/MENKES/813/2019 TENTANG FORMULARIUM NASIONAL', 8(5), p. 55.
- Khan, S. H. and Zaidi, S. K. (2020) 'Review of evidence on using ACEi and ARBs in patients with hypertension and COVID-19', *Drugs and Therapy Perspectives*, 36(8), pp. 347–350. doi: 10.1007/s40267-020-00750-w.
- Khattak, Z. and Vlachadis Castles, A. (2021) 'Prescription of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blocking Agents in Australia During the COVID-19 Pandemic', *Heart, Lung and Circulation*, 30, pp. S113–S114. doi: 10.1016/j.hlc.2021.06.048.
- Kim, H. J. *et al.* (2017) 'Effects of valsartan and amlodipine on oxidative stress in type 2 diabetic patients with hypertension: A randomized, multicenter study', *Korean Journal of Internal Medicine*, 32(3), pp. 497–504. doi: 10.3904/kjim.2015.404.
- Kocayigit, I. *et al.* (2020) 'Impact of antihypertensive agents on clinical course and in-hospital mortality: Analysis of 169 hypertensive patients hospitalized for COVID-19', *Revista da Associacao Medica Brasileira*, 66(Suppl 2), pp. 71–76. doi: 10.1590/1806-9282.66.S2.71.
- Kreutz, R. *et al.* (2020) 'Hypertension , the renin – angiotensin system , and the risk of lower respiratory tract infections and lung injury : implications for COVID-19 European Society of Hypertension COVID-19 Task Force Review of Evidence', pp. 1–12. doi: 10.1093/cvr/cvaa097.
- Kuba, K. *et al.* (2005) 'A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus – induced lung injury', 11(8), pp. 875–879. doi: 10.1038/nm1267.
- Kuster, G. M. and Osswald, S. (2020) 'Switching antihypertensive therapy in times of COVID-19: Why we should wait for the evidence', *European Heart Journal*, 41(19), p. 1857. doi: 10.1093/eurheartj/ehaa335.
- Lam, K. W. *et al.* (2020) 'Continued in-hospital angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker use in hypertensive COVID-19 patients is associated with positive clinical outcome', *Journal of Infectious Diseases*, 222(8), pp. 1256–1264. doi: 10.1093/infdis/jiaa447.
- Laurent, S. (2017) 'Antihypertensive drugs', *Pharmacological Research*, 124, pp. 116–125. doi: 10.1016/j.phrs.2017.07.026.
- Lebek, S. *et al.* (2020) 'Angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker treatment and haemodynamic factors are associated

- with increased cardiac mRNA expression of angiotensin-converting enzyme 2 in patients with cardiovascular disease', *European Journal of Heart Failure*, 22(12), pp. 2248–2257. doi: 10.1002/ejhf.2020.
- Lezama-martinez, D. *et al.* (2018) 'Combined Antihypertensive Therapies That Increase Expression of Cardioprotective Biomarkers Associated With the Renin – Angiotensin and Kallikrein – Kinin Systems', 72(6), pp. 291–295.
- Li, B. *et al.* (2020) 'Hypertensive rats treated chronically with Nw-Nitro-L-Arginine Methyl Ester (L-NAME) induced disorder of hepatic fatty acid metabolism and intestinal pathophysiology', *Frontiers in Pharmacology*, 10(January), pp. 1–17. doi: 10.3389/fphar.2019.01677.
- Li, Yingchuan *et al.* (2015) 'Angiotensin-Converting Enzyme Inhibition Attenuates Lipopolysaccharide-Induced Lung Injury By Regulating The Balance Between Angiotensin-Converting Enzyme And Angiotensin-Converting Enzyme 2 And Inhibiting Mitogen-Activated Protein Kinase Activation', 43(4). doi: 10.1097/SHK.0000000000000302
- Lilly, L. S. (2011) *Pathophysiology of heart disease*. 5th edn. Edited by Leonard S. Lilly. Philadelphia: Wolters Kluwer Lippincott Williams & Wilkins.
- Lubbe, L. *et al.* (2020) 'ACE2 and ACE : structure-based insights into mechanism , regulation and receptor recognition by SARS-CoV', 0(November), pp. 2851–2871.
- Mahmoudpour, S. H. *et al.* (2016) 'Determinants of angiotensin-converting enzyme inhibitor (ACEI) intolerance and angioedema in the UK Clinical Practice Research Datalink', *British Journal of Clinical Pharmacology*, 82(6), pp. 1647–1659. doi: 10.1111/bcp.13090.
- Mancia, G. *et al.* (2018) '2018 ESC/ESH Guidelines for the management of arterial hypertension', *European Heart Journal*, 39(6), pp. 3021–3104. doi: doi:10.1093/eurheartj/ehy339.
- Mason, R. J. (2020) 'Pathogenesis of COVID-19 from a cell biology perspective', *European Respiratory Journal*, 55(4), pp. 9–11. doi: 10.1183/13993003.00607-2020.
- Messerli, F. H. *et al.* (2018) 'Angiotensin-Converting Enzyme Inhibitors in Hypertension: To Use or Not to Use?', *Journal of the American College of Cardiology*, 71(13), pp. 1474–1482. doi: 10.1016/j.jacc.2018.01.058.
- Mills, K. T., Stefanescu, A. and He, J. (2020) 'The global epidemiology of hypertension', *Nature Reviews Nephrology*, 16(4), pp. 223–237. doi: 10.1038/s41581-019-0244-2.
- Mizuiru, S. (2015) 'ACE and ACE2 in kidney disease', *World Journal of Nephrology*, 4(1), p. 74. doi: 10.5527/wjn.v4.i1.74.
- Mondaca-Ruff, D. *et al.* (2019) 'Angiotensin II-regulated autophagy is required for vascular smooth muscle cell hypertrophy', *Frontiers in Pharmacology*, 10(February), pp. 1–13. doi: 10.3389/fphar.2018.01553.
- Montinaro, V. and Cicardi, M. (2020) 'ACE inhibitor-mediated angioedema', *International Immunopharmacology*, 78(November 2019), p. 106081. doi: 10.1016/j.intimp.2019.106081.

- Nair, A. and Jacob, S. (2016) 'A simple practice guide for dose conversion between animals and human', *Journal of Basic and Clinical Pharmacy*, 7(2), p. 27. doi: 10.4103/0976-0105.177703.
- Nour-Eddine Rhaleb, Xiao-Ping Yang, O. A. C. (2011) 'The Kallikrein-Kinin System as a Regulator of Cardiovascular and Renal Function', *Comprehensive Physiology*, 1(2), pp. 971–993. doi: 10.1002/cphy.c100053.
- Nursela Hijriani, Lilik Yusetyani, D. H. (2020) 'The effect of curcuma (*Curcuma xanthorrhiza* roxb .) extract as an adjuvant of captopril therapy on cardiac histopathology of male mice (*Mus musculus*) with hypertension Abstract':, *Journal of Basic and CLlinical Physiology and Pharmacology*, pp. 1–7. doi: 10.1515/jbcpp-2019-0280.
- Patel, V. B. *et al.* (2017) 'HHS Public Access', 118(8), pp. 1313–1326. doi: 10.1161/CIRCRESAHA.116.307708.Role.
- Pechanova, O., Vrankova, S. and Cebova, M. (2020) 'Chronic L-Name-Treatment Produces Hypertension by Di ff erent Mechanisms in Peripheral Tissues and Brain : Role of Central eNOS', pp. 46–54.
- Pinto-Sietsma, S.-J. *et al.* (2020) 'Antihypertensive drugs in COVID-19 infection', *European Heart Journal - Cardiovascular Pharmacotherapy*, 6(6), pp. 415–416. doi: 10.1093/ehjcvp/pvaa058.
- Pinto, B. G. G. *et al.* (2020) 'ACE2 Expression Is Increased in the Lungs of Patients With Comorbidities Associated With Severe COVID-19', *The Journal of Infectious Diseases*, 222(4), pp. 556–563. doi: 10.1093/infdis/jiaa332.
- Pranata, R. *et al.* (2020) 'Hypertension is associated with increased mortality and severity of disease in COVID-19 pneumonia: A systematic review, meta-analysis and meta-regression', *JRAAS - Journal of the Renin-Angiotensin-Aldosterone System*, 21(2). doi: 10.1177/1470320320926899.
- Prof. Giovanni de Simone (2020) 'Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers', *European Society of Cardiology*, pp. 1–1.
- Pubmed (2022) *Index @ Pubmed.Ncbi.Nlm.Nih.Gov, National Library of Medicine.* Available at: <https://pubmed.ncbi.nlm.nih.gov/?term=ace2&filter=years.1981-2004&timeline=expanded> (Accessed: 22 January 2022).
- Reich, H. N. *et al.* (2008) 'Decreased glomerular and tubular expression of ACE2 in patients with type 2 diabetes and kidney disease', *Kidney International*, 74(12), pp. 1610–1616. doi: <https://doi.org/10.1038/ki.2008.497>.
- Rysz, J. *et al.* (2020) 'Pharmacogenomics of hypertension treatment', *International Journal of Molecular Sciences*, 21(13), pp. 1–26. doi: 10.3390/ijms21134709.
- Saheb Sharif-Askari, N. *et al.* (2020) 'Effect of Common Medications on the Expression of SARS-CoV-2 Entry Receptors in Kidney Tissue', *Clinical*

- and Translational Science*, 13(6), pp. 1048–1054. doi: 10.1111/cts.12862.
- Saiz, L. C. *et al.* (2020) 'Blood pressure targets for the treatment of people with hypertension and cardiovascular disease', *Cochrane Database of Systematic Reviews*, 2020(9). doi: 10.1002/14651858.CD010315.pub4.
- Sherwood and Lauralee (2014) 'Fisiologi Manusia Ed. 8', 6, pp. 1–999.
- Semenzato, L. *et al.* (2021) 'Antihypertensive Drugs and COVID-19 Risk: A Cohort Study of 2 Million Hypertensive Patients', *Hypertension*, 77(3), pp. 833–842. doi: 10.1161/HYPERTENSIONAHA.120.16314.
- Sica, D. A. (2006) 'Pharmacotherapy review: calcium channel blockers.', *Journal of clinical hypertension (Greenwich, Conn.)*, 8(1), pp. 53–56. doi: 10.1111/j.1524-6175.2005.04140.x.
- Silva, I. V. G., De Figueiredo, R. C. and Rios, D. R. A. (2019) 'Effect of different classes of antihypertensive drugs on endothelial function and inflammation', *International Journal of Molecular Sciences*, 20(14), pp. 5–9. doi: 10.3390/ijms20143458.
- Sinha, S. *et al.* (2020) 'In vitro and in vivo identification of clinically approved drugs that modify ACE 2 expression', *Molecular Systems Biology*, 16(7), pp. 1–9. doi: 10.15252/msb.20209628.
- Smith, J. C. *et al.* (2020) 'Cigarette Smoke Exposure and Inflammatory Signaling Increase the Expression of the SARS-CoV-2 Receptor ACE2 in the Respiratory Tract', *Developmental Cell*, 53(5), pp. 514–529.e3. doi: <https://doi.org/10.1016/j.devcel.2020.05.012>.
- Solaimanzadeh, I. (2020) 'Nifedipine and Amlodipine Are Associated With Improved Mortality and Decreased Risk for Intubation and Mechanical Ventilation in Elderly Patients Hospitalized for COVID-19', *Cureus*, 12(5). doi: 10.7759/cureus.8069.
- Soria-castro, E. *et al.* (2016) 'Peroxisome proliferator-activated receptor- a stimulation by clofibrate favors an antioxidant and vasodilator environment in a stressed left ventricle', 68, pp. 692–702. doi: 10.1016/j.pharep.2016.03.002.
- Specht, P. A., Moll, G. N. and Woensel, J. B. Van (2011) 'Acute respiratory distress syndrome leads to reduced ratio of ACE / ACE2 activities and is prevented by angiotensin- (1 – 7) or an angiotensin II receptor antagonist', 1, pp. 618–627.
- Takai, S. *et al.* (2013) 'Powerful vascular protection by combining cilnidipine with valsartan in stroke-prone, spontaneously hypertensive rats', *Hypertension Research*, 36(4), pp. 342–348. doi: 10.1038/hr.2012.187.
- Trifirò, G. *et al.* (2020) 'Should Patients Receiving ACE Inhibitors or Angiotensin Receptor Blockers be Switched to Other Antihypertensive Drugs to Prevent or Improve Prognosis of Novel Coronavirus Disease 2019 (COVID-19)?', *Drug Safety*, 43(6), pp. 507–509. doi: 10.1007/s40264-020-00935-2.
- Unger, T. *et al.* (2020) '2020 International Society of Hypertension Global Hypertension Practice Guidelines', *Hypertension*, 75(6), pp. 1334–

1357. doi: 10.1161/HYPERTENSIONAHA.120.15026.
- Vaduganathan, M. *et al.* (2020) 'Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19', *New England Journal of Medicine*, 382(17), pp. 1653–1659. doi: 10.1056/nejmsr2005760.
- Whelton, P. K. *et al.* (2018) 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: Executive summary: A report of the American college of cardiology/American Heart Association task force on practice guidelines. *Hypertension*. doi: 10.1161/HYP.000000000000066.
- WHO (2020) 'COVID-19 and the use of angiotensin-converting enzyme inhibitors and receptor blockers. Scientific brief', *Scientific Brief*, 16(1), pp. 120–121. doi: 10.15557/PiMR.2020.0023.
- WHO (2021a) 'Guideline for the Pharmacological treatment of hypertension in adults', *World Health Organization*.
- WHO (2021b) 'Hypertension'. World Health Organization. Available at: https://www.who.int/health-topics/hypertension#tab=tab_1.
- Wysocki, J. *et al.* (2020) 'Kidney and Lung ACE2 Expression after an ACE Inhibitor or an Ang II Receptor Blocker: Implications for COVID-19', *Journal of the American Society of Nephrology*, 31(9), pp. 1941–1943. doi: 10.1681/ASN.2020050667.
- Xiong, Q. *et al.* (2022) 'Close relatives of MERS-CoV in bats use ACE2 as their functional receptors', *Nature*, 612(7941), pp. 748–757. doi: 10.1038/s41586-022-05513-3.
- Xudong, X. *et al.* (2006) 'Age- and gender-related difference of ACE2 expression in rat lung', *Life Sciences*, 78(19), pp. 2166–2171. doi: <https://doi.org/10.1016/j.lfs.2005.09.038>.
- Xue, Y. *et al.* (2020) 'Effects of ACEI and ARB on COVID-19 patients: A meta-analysis', *JRAAS - Journal of the Renin-Angiotensin-Aldosterone System*, 21(4). doi: 10.1177/1470320320981321.
- Yan, F. *et al.* (2020) 'Antihypertensive drugs are associated with reduced fatal outcomes and improved clinical characteristics in elderly COVID-19 patients', *Cell Discovery*, 6(1). doi: 10.1038/s41421-020-00221-6.
- Yang, J. *et al.* (2020) 'Molecular interaction and inhibition of SARS-CoV-2 binding to the ACE2 receptor', *Nature Communications*, 11(1). doi: 10.1038/s41467-020-18319-6.
- Yılmaz, İ. (2019) 'Angiotensin-converting enzyme inhibitors induce cough', *Turkish Thoracic Journal*, 20(1), pp. 36–42. doi: 10.5152/TurkThoracJ.2018.18014.
- Yogiantoro, M. (2014) 'Pendekatan Klinis Hipertensi', in Siti Setiati, Idrus Alwi, Aru W. Sudoyo, Marcellus Simadibrata, Bambang Setiyohadi, A. F. S. (ed.) *Buku Ajar Ilmu Penyakit Dalam*. 6th edn. Jakarta: Interna Publishing, pp. 2261–2265.
- Zhang, L. K. *et al.* (2020) 'Calcium channel blocker amlodipine besylate therapy is associated with reduced case fatality rate of COVID-19 patients with

- hypertension', *Cell Discovery*, 6(1). doi: 10.1038/s41421-020-00235-0.
- Zhang, X. *et al.* (2020) 'ACE2 and COVID-19 and the resulting ARDS', *Postgraduate Medical Journal*, pp. 403–407. doi: 10.1136/postgradmedj-2020-137935.
- Zhou, F. *et al.* (2020) 'Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study', *The Lancet*, 395(10229), pp. 1054–1062. doi: 10.1016/S0140-6736(20)30566-3.